MS4A1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift: 100%.
Raji
Human
Lymphatic
Next Generation Sequencing, Western blot
Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift: 100%
APY, ATOPY, B-lymphocyte antigen CD20, B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, B1, Bp 35, CD20 antigen, CD20 receptor, CD20_HUMAN, CVID 5, FCER1B, Fc Fragment of IgE high affinity I receptor for beta polypeptide, Fc epsilon receptor I beta chain, High affinity immunoglobulin epsilon receptor subunit beta, IGEL, IGER, IGHER, IgE Fc receptor subunit beta, Leu-16, Leukocyte surface antigen Leu-16, Ly44, MGC3969, MS4A1, Membrane spanning 4 domains subfamily A member 2, Membrane-spanning 4-domains subfamily A member 1, S7, membrane-spanning 4-domains A1
MS4A1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift: 100%.
Raji
Human
Lymphatic
Next Generation Sequencing, Western blot
Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift: 100%
Lymphoma
MS4A1
Knockout
CRISPR technology
Next Generation Sequencing, Western blot
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
EU: 2 US: 2
Suspension
Male
Ambient - Can Ship with Ice
-20°C
-20°C
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
This supplementary information is collated from multiple sources and compiled automatically.
CD20 also known as MS4A1 or L26 is a membrane-spanning 4-domains subfamily A member 1 protein. It is a non-glycosylated phosphoprotein with a molecular mass of approximately 33-37 kDa. Expressed extensively on the surface of B-cells CD20 plays an important role in B-cell activation and regulation. While CD20 is absent on early pro-B cells and plasma cells its presence increases as B-cells mature. Anti-CD20 antibodies such as 2H7 are commonly used in research and treatment to deplete B-cells due to the target's consistent expression in most stages of B-cell development.
CD20 contributes significantly to calcium ion transport which is essential for the activation process of B-cells. Although CD20 does not belong to a larger protein complex its role centers around forming a calcium channel that allows a sustained influx of calcium into the B-cells. This influx is important for the signaling pathways that govern B-cell activation proliferation and differentiation impacting the immune response efficacy.
CD20 is closely involved in the B-cell receptor (BCR) signaling pathway and the Fc gamma R-mediated phagocytosis pathway. These pathways play vital roles in adaptive immunity and immune response modulation. CD20's interaction with proteins like PI3K during BCR signaling enhances receptor-mediated cellular signals subsequently influencing downstream effectors involved in cell growth and survival of B-cells.
CD20 is strongly linked to certain blood cancers and autoimmune diseases including non-Hodgkin's lymphoma and rheumatoid arthritis. These conditions often exploit aberrant B-cell activity or count. CD20's expression on malignant B-cells in non-Hodgkin's lymphoma makes it an effective target for monoclonal antibody therapies such as rituximab an anti-CD20 antibody. Additionally CD20-targeted therapies can help deplete pathogenic B-cells in rheumatoid arthritis highlighting the protein's relevance in disease treatment.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lanes 1 - 4: Western blot - Anti-CD20 antibody [EP459Y] (Anti-CD20 antibody [EP459Y] ab78237) at 1/1000 dilution
Lanes 1 - 4: Western blot - Anti-CD20 antibody [EP459Y] - Rat IgG2a (Chimeric) (Anti-CD20 antibody [EP459Y] - Rat IgG2a (Chimeric) ab279300) at 1/1000 dilution
Lane 1: Wild-type Raji cell lysate at 20 µg
Lane 2: MS4A1 knockout Raji cell lysate at 20 µg
Lane 3: A549 cell lysate at 20 µg
Lane 4: HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 21 kDa, 33 kDa
Observed band size: 33 kDa
Lane 1: Wild-type Raji cell lysate 20 μg
Lane 2: MS4A1 knockout Raji cell lysate 20 μg
Lane 3: A549 cell lysate 20 μg
Lane 4: HeLa cell lysate 20 μg
False colour image of Western blot: Anti-CD20 antibody [EP459Y] – Mouse IgG2a (Chimeric) staining at 1/1000 dilution, shown in green; Rabbit anti-alpha Tubulin antibody [EP1332Y] (Anti-alpha Tubulin antibody [EP1332Y] - Microtubule Marker ab52866) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-CD20 antibody [EP459Y] - Mouse IgG2a (Chimeric) ab279299 was shown to bind specifically to CD20. A band was observed at 33 kDa in wild-type Raji cell lysates with no signal observed at this size in MS4A1 knockout cell line Human MS4A1 (CD20) knockout Raji cell line ab273871 (knockout cell lysate Human MRPS28 knockout HEK-293T cell lysate ab263259). To generate this image, wild-type and MS4A1 knockout Raji cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1% Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/20000 dilution.
Lanes 1 - 4: Western blot - Anti-CD20 antibody [EP459Y] (Anti-CD20 antibody [EP459Y] ab78237) at 1/1000 dilution
Lanes 1 - 4: Western blot - Anti-CD20 antibody [EP459Y] - Mouse IgG2a (Chimeric) (Anti-CD20 antibody [EP459Y] - Mouse IgG2a (Chimeric) ab279299) at 1/1000 dilution
Lane 1: Wild-type Raji cell lysate at 20 µg
Lane 2: MS4A1 knockout Raji cell lysate at 20 µg
Lane 3: A549 cell lysate at 20 µg
Lane 4: HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 21 kDa, 33 kDa
Observed band size: 33 kDa
Lane 1: Wild-type Raji cell lysate 20 μg
Lane 2: MS4A1 knockout Raji cell lysate 20 μg
Lane 3: A549 cell lysate 20 μg
Lane 4: HeLa cell lysate 20 μg
False colour image of Western blot: Anti-CD20 antibody [EP459Y] - Mouse IgG1 (Chimeric) staining, shown in green; Rabbit anti-alpha Tubulin antibody [EP1332Y] (Anti-alpha Tubulin antibody [EP1332Y] - Microtubule Marker ab52866) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-CD20 antibody [EP459Y] - Mouse IgG1 (Chimeric) ab279298 was shown to bind specifically to CD20. A band was observed at 33 kDa in wild-type Raji cell lysates with no signal observed at this size in MS4A1 knockout cell line Human MS4A1 (CD20) knockout Raji cell line ab273871 (knockout cell lysate Human MRPS28 knockout HEK-293T cell lysate ab263259). To generate this image, wild-type and MS4A1 knockout Raji cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/20000 dilution.
Lanes 1 - 4: Western blot - Anti-CD20 antibody [EP459Y] - Mouse IgG1 (Chimeric) (Anti-CD20 antibody [EP459Y] - Mouse IgG1 (Chimeric) ab279298) at 1/1000 dilution
Lanes 1 - 4: Western blot - Anti-CD20 antibody [EP459Y] (Anti-CD20 antibody [EP459Y] ab78237) at 1/1000 dilution
Lane 1: Wild-type Raji cell lysate at 20 µg
Lane 2: MS4A1 knockout Raji cell lysate at 20 µg
Lane 3: A549 cell lysate at 20 µg
Lane 4: HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 21 kDa, 33 kDa
Observed band size: 33 kDa
Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift: 100%
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com